2023
Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)
Stoller S, Capozza S, Alberti P, Lustberg M, Kleckner I. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Supportive Care In Cancer 2023, 31: 293. PMID: 37086308, DOI: 10.1007/s00520-023-07734-2.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsHumansNeurotoxicity SyndromesPeripheral Nervous System DiseasesPhysical TherapistsQuality of LifeConceptsChemotherapy-induced peripheral neurotoxicityPhysical therapy guidelinesPhysical therapistsPhysical therapyCIPN assessmentPeripheral neurotoxicityOncology teamTherapy guidelinesHome-based exercise prescriptionBurden of chemotherapyManual therapy interventionsClinical practice guidelinesPhysical therapy assessmentLimited effective treatmentsQuality of lifePhysical performance measuresSymptom management researchCIPN treatmentNeurologic symptomsMotor dysfunctionPatient functionExercise prescriptionAerobic trainingChemotherapy agentsPractice guidelines
2022
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity
Nepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y, DiGiacomo D, Gibson A, Lustberg M, Hu S, Sparreboom A. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. Cancer Research Communications 2022, 2: 1334-1343. PMID: 36506732, PMCID: PMC9730833, DOI: 10.1158/2767-9764.crc-22-0172.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDuloxetine HydrochlorideHumansMiceNeurotoxicity SyndromesOxaliplatinPeripheral Nervous System DiseasesConceptsDRG neuronsPeripheral neurotoxicitySide effectsOxaliplatin-Induced Peripheral NeurotoxicityOxaliplatin-based regimensOxaliplatin-based treatmentPharmacokinetics of oxaliplatinEffect of duloxetineMouse DRG neuronsWild-type miceCytotoxicity of oxaliplatinConcentration-dependent mannerColorectal cancerCancer patientsPlasma levelsOIPNPlasma pharmacokineticsDuloxetinePrevention strategiesTherapeutic candidateOxaliplatinTumor cell linesTranslational feasibilityMiceComplete protection
2020
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson A, Li Y, Hong KW, DiGiacomo D, Xia S, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg M, Cavaletti G, Pabla N, Hu S, Sparreboom A. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. Journal Of Clinical Investigation 2020, 130: 4601-4606. PMID: 32484793, PMCID: PMC7456253, DOI: 10.1172/jci136796.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsFemaleMaleMiceMice, KnockoutNeurogliaNeuronsNeurotoxicity SyndromesOrganic Cation Transporter 2OxaliplatinRatsConceptsOrganic cation transporter 2Peripheral neurotoxicityColorectal cancerOxaliplatin-induced peripheral neurotoxicityOxaliplatin-containing therapyOxaliplatin-induced neurotoxicitySatellite glial cellsOxaliplatin neurotoxicityChronic formCancer patientsGlial cellsPreclinical modelsPreventive strategiesMouse modelPharmacological approachesPharmacological targetingTranslational significanceNeurotoxicityTransporter 2PatientsUptake transportersCancerAnticancer drugsCandidate transportersSolute carriers